• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical Research89bio
    Picture of 89bio logo

    ETNB — 89bio Share News

    $14.760.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    • Market Cap
      $2.19bn
    • Enterprise Value
      $1.67bn
    • Revenue
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • ETNB Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    ETNB Dividends
    • Brief: 89Bio Announces U.S. FDA Has Granted Breakthrough Therapy Designation For Pegozafermin In Nonalcoholic Steatohepatitis

      21/09/2023 13:19
    • U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals

      16/08/2023 08:15
    • Brief: 89Bio Inc - On August 10, Gregory Grunberg Notified Board Of His Intent To Resign As A Member Of Board

      15/08/2023 23:16
    • 89Bio Inc reports results for the quarter ended in June - Earnings Summary

      09/08/2023 21:49
    • Brief: 89bio, Inc. Q2 basic EPS USD -0.52

      09/08/2023 21:43
    • 89Bio Inc expected to post a loss of 41 cents a share - Earnings Preview

      07/08/2023 19:35
    • U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics

      13/06/2023 19:08
    • U.S. STOCKS ON THE MOVE-Comerica, copper miners, Journey Medical

      13/06/2023 17:35
    • 89Bio up as Evercore starts with 'outperform', says NASH asset undervalued

      13/06/2023 15:14
    • Brief: 89Bio Initiates Phase 3 Entrust Trial Of Pegozafermin In Patients With Severe Hypertriglyceridemia (SHTG)

      23/05/2023 13:19
    • 89Bio Inc reports results for the quarter ended in March - Earnings Summary

      09/05/2023 13:00
    • Health Rounds: New fatty liver drug shows promise in monkeys

      11/04/2023 17:03
    • U.S. RESEARCH ROUNDUP- Enliven Therapeutics, Lululemon Athletica, Walgreens

      29/03/2023 08:03
    • Brief: 89Bio Inc - Files Prospectus For Offering Of Up To 16.9 Million Shares Of Common Stock

      27/03/2023 21:44
    • U.S. STOCKS ON THE MOVE-CalciMedica, Natgas firms,

      24/03/2023 17:52
    • U.S. STOCKS ON THE MOVE-ReNew Energy, First Horizon, Block Inc

      24/03/2023 16:28
    • U.S. STOCKS ON THE MOVE-Incyte Corp, Netflix Inc, Comerica Inc

      24/03/2023 14:58
    • 89Bio lifts after pricing upsized $275 mln stock offering

      24/03/2023 12:20
    • Brief: 89Bio Inc Announces Upsized Pricing Of $275 Million Public Offering Of Common Stock

      24/03/2023 11:21
    • 89Bio soars to 16-month high ahead of planned equity raise

      23/03/2023 17:00
    Previous12345Next

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.